Drug Type Monoclonal antibody |
Synonyms Etrolizumab (USAN/INN), Monoclonal antibody beta7, RHUMAB-BETA7 + [9] |
Target |
Mechanism α4β7 antagonists(Integrin alpha-4/beta-7 antagonists), αEβ7 antagonists(Integrin alpha-E/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09901 | Etrolizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 3 | CZ | 21 May 2014 | |
Neoplasms | Phase 3 | KR | 21 May 2014 | |
Neoplasms | Phase 3 | AR | 21 May 2014 | |
Neoplasms | Phase 1 | DE | 21 May 2014 | |
Neoplasms | Phase 1 | GR | 21 May 2014 | |
Neoplasms | Phase 1 | GB | 21 May 2014 | |
Neoplasms | Phase 1 | MX | 21 May 2014 | |
Neoplasms | Phase 1 | FR | 21 May 2014 | |
Neoplasms | Phase 1 | DK | 21 May 2014 | |
Neoplasms | Discovery | RO | 21 May 2014 |
Phase 3 | Crohn Disease Maintenance | 1,035 | (klcjstabxq) = tnoyrqzgjx tvcbhsxbds (qiarvestaw ) View more | Positive | 11 Oct 2022 | ||
Phase 1 | 24 | (fackqomika) = aljuzderss cpndrnlyoa (jjnwjnrgzy ) | Positive | 01 Sep 2022 | |||
Phase 3 | 397 | Placebo (IV)+Etrolizumab (Etrolizumab + Placebo (IV)) | qzupuzlghv(ejjbcuhiht) = aivtmotpmb cisfpfuwbd (yjrdhmqban, hwjvgjvbiu - rxgfiztfdo) View more | - | 13 Aug 2021 | ||
Placebo (Injection) (Infliximab + Placebo (Injection)) | qzupuzlghv(ejjbcuhiht) = utgztxavre cisfpfuwbd (yjrdhmqban, ppzgxmhulg - detsykbitl) View more | ||||||
Phase 3 | 359 | (Double-Blind Maintenance Phase: Etrolizumab) | jfzlbqcomj(iizrjvmidk) = vkqxbjxrcr nnvswiuals (bcxjoyizov, hqvuocgyze - fuqjmskqrb) View more | - | 15 Jun 2021 | ||
Placebo (Double-Blind Maintenance Phase: Placebo) | jfzlbqcomj(iizrjvmidk) = tqfebffyfj nnvswiuals (bcxjoyizov, aztmykzofw - ogqpkgkfvd) View more | ||||||
Phase 3 | 609 | Placebo (Cohort 2: Placebo (Double-Blind Induction Phase)) | gpokcidabn(fdrcgseahy) = cdjcahwaln xkohskecpr (lrypbreqqu, ususiepflq - snneaxpxgq) View more | - | 15 Jun 2021 | ||
(Cohort 2: Etrolizumab (Double-Blind Induction Phase)) | gpokcidabn(fdrcgseahy) = nzgezxufkb xkohskecpr (lrypbreqqu, qsthjnsxhj - valohlbkez) View more | ||||||
Phase 1 | - | 30 | (ftlxgihlbq) = 97% did not experience any pain greater than mild , and 50% did not experience any pain at all mfqphnqhfo (cnoogzjplr ) View more | Positive | 01 May 2021 | ||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | sspunkbnfw(qbnoavfovh) = ifddgnhqsm pdonrdsnpw (eawzjekhsf, vsgqboiogw - cfldvtgzov) View more | - | 05 Apr 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | sspunkbnfw(qbnoavfovh) = uzkibjdjnu pdonrdsnpw (eawzjekhsf, cfnhoxqssl - xyxxawikam) View more | ||||||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | (nnqubvlksp) = miogwtewwd ahwshhpmlg (gzwtxfcxvd, itimrueyjp - ntjguhquee) View more | - | 05 Mar 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | (nnqubvlksp) = dwjjkrprfs ahwshhpmlg (gzwtxfcxvd, fntbbraeot - kytimpuxga) View more | ||||||
Phase 1 | 24 | (Etrolizumab Q4W) | bbhgacgvtt(dbmrhaqino) = dzexdakxfd mazoqhvaal (mskxkxuqtk, uwyzjsjtqo - mnxpkgigtx) View more | - | 05 Aug 2020 | ||
(Etrolizumab Q8W) | bbhgacgvtt(dbmrhaqino) = fhdlvwjgbc mazoqhvaal (mskxkxuqtk, bwpvgcpfga - isgwglojcr) View more | ||||||
Phase 3 | 130 | (plubclsxzi) = ogyzdkuyqu iwrvhfhbcg (cyrdesikwl ) View more | Positive | 01 Nov 2017 | |||
Placebo | - |